DOCSLIB.ORG

Analysis of Insulin Analogs and the Strategy of Their Further Development

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Analysis of Insulin Analogs and the Strategy of Their Further Development ISSN 0006-2979, Biochemistry (Moscow), 2018, Vol. 83, Suppl. 1, pp. S146-S162. © Pleiades Publishing, Ltd., 2018. Original Russian Text © O. M. Selivanova, S. Yu. Grishin, A. V. Glyakina, A. S. Sadgyan, N. I. Ushakova, O. V. Galzitskaya, 2018, published in Uspekhi Biologicheskoi Khimii, 2018, Vol. 58, pp. 313-346. REVIEW Analysis of Insulin Analogs and the Strategy of Their Further Development O. M. Selivanova1, S. Yu. Grishin1,2, A. V. Glyakina1,3, A. S. Sadgyan4, N. I. Ushakova4, and O. V. Galzitskaya1* 1Institute of Protein Research, Russian Academy of Sciences, 142290 Pushchino, Moscow Region, Russia; E-mail: [email protected] 2Lomonosov Moscow State University, 119991 Moscow, Russia 3Institute of Mathematical Problems of Biology, Keldysh Institute of Applied Mathematics, Russian Academy of Sciences, 142290 Pushchino, Moscow Region, Russia 4Joint-Stock Scientific Production Association Bioran, 119261 Moscow, Russia Received June 5, 2017 Revision received July 9, 2017 Abstract—We analyzed the structural properties of the peptide hormone insulin and described the mechanism of its physio- logical action, as well as effects of insulin in type 1 and 2 diabetes. Recently published data on the development of novel insulin preparations based on combining molecular design and genetic engineering approaches are presented. New strate- gies for creation of long-acting insulin analogs, the mechanisms of functioning of these analogs and their structure are dis- cussed. Side effects of insulin preparations are described, including amyloidogenesis and possible mitogenic effect. The pathways for development of novel insulin analogs are outlined with regard to the current requirements for therapeutic preparations due to the wider occurrence of diabetes of both types. DOI: 10.1134/S0006297918140122 Keywords: insulin analogs, diabetes, hyperglycemia, hypoglycemia, glycemic control, insulin fibrils Insulin is a peptide hormone (51 a.a.) produced by Insulin is produced in response to the rise of glucose the β-cells of the pancreatic Langerhans islets. An insulin blood concentration; it binds to the insulin receptor (IR) monomer consists of two polypeptide chains: A (21 a.a.) and activates glucose transporters, mainly Glut4, in fat and B (30 a.a.) connected via two disulfide bridges tissues and cardiac and skeletal muscles. Mobilized formed by cysteine residues at positions A7–B7 and transporters are recruited from the intracellular compart- A20–B19. The third intrasubunit S–S bond is formed ments to the plasma membrane, where they facilitate glu- between the residues A6 and A11. Although insulin was cose transport into the cell [2]. If insulin production is discovered at the beginning of the XX century [1], the disrupted, the blood concentration of glucose increases studies of its functions have remained relevant up to pres- (chronic hyperglycemia), which is the basic diagnostic ent time. symptom of type 1 diabetes [3]. Type 2 diabetes develops Insulin regulates a number of metabolic processes, when the IR signaling is disturbed, even if the hormone is such as biosynthesis of proteins, fats, and nucleic acids, produced in sufficient amounts; it is characterized by the as well as cell growth and differentiation. However, its key decreased tissue sensitivity to insulin (insulin resistance) function is regulation of glucose uptake by the cells. [4-6]. Diabetes is classified as a group of metabolic diseases Abbreviations: αCT, C-terminal domain of insulin receptor α- characterized by hyperglycemia caused by defects in the subunit; BMI, body mass index; ER, endoplasmic reticulum; insulin secretion or insulin action [7]. Both reduced cell IR, insulin receptor; IGF-1R, type 1 insulin-like growth factor sensitivity to insulin and inadequate insulin levels in the receptor; IRA, insulin receptor isoform A; IRB, insulin recep- tor isoform B; L1, leucine-rich repeat domain of the insulin type 2 and 1 diabetes lead to development of such com- receptor α-subunit; NPH, neutral protamine Hagedorn; PEG, plications, as vascular diseases, in particular coronary polyethylene glycol; ThT, thioflavin T. heart disease, cerebrovascular disorders, retinopathy, * To whom correspondence should be addressed. nephropathy, and neuropathy [8]. Impairments in insulin S146 ANALYSIS OF INSULIN ANALOGS S147 secretion and functioning can be found in the same erences of patients should be taken into account during patient, which makes revealing the major cause of hyper- the therapy [16]. glycemia rather problematic. The immune response of an The limitations in the use of insulin are related to the organism to its own β-cells in the pancreas can be diag- necessity of administration of exact doses several times a nosed from the presence of autoantibodies against day in order to maintain physiological levels of glucose in insulin, Langerhans islet cells, tyrosine phosphatases IA2 the blood. Besides, the hormone has a narrow therapeu- and IA2β, and glutamate decarboxylase GAD 65. An tic window associated with the risk of hyperglycemia; it increased risk of type 1 diabetes development can be can also cause weight gain that might be dangerous in revealed by molecular genetic analysis of the HLA–DQB1 patients with a high body mass index (BMI) [17, 18]. gene alleles [9, 10]. As a rule, insulin secretion at the last The above problems that are associated with the stage of diabetes is insignificant or lacking at all, which is properties of native human insulin have promoted the indicated by low blood plasma levels of the C-peptide. development of its analogs (Fig. 1). Patients with type 1 diabetes become dependent on Insulin analogs are synthetically modified molecules insulin administration. that, due to faster or more prolonged action, allow better Only 5-10% diabetes patients have type 1 diabetes, metabolic control of the blood glucose levels in diabetes while most patients have type 2 diabetes [7]. Although no [20]. By the present time, different preparations for dia- autoimmune destruction of cells takes place in type 2 dia- betes therapy have been created that include insulin betes, this type of diabetes can be caused by various other analogs and mixtures. factors. The precise mechanisms of type 2 diabetes are Herein, we review existing insulin analogs. There are extensively studied [11-15]. Most cases of insulin usage two main strategies for their development: creation of are associated with type 2 diabetes, because it has a high- bolus (short-acting) and basal (long-acting) insulin er occurrence. preparations. These types of insulin analogs can be com- The efficiency of insulin in diabetes treatment that is bined to normalize glucose blood levels and to provide the related to the ability of this hormone to decrease the delivery of the preparations in a form convenient for blood glucose levels has been demonstrated during patients. decades of insulin use in medical practice. However, at The use of insulin as a drug has started almost imme- present, novel approaches to the diabetes therapy remain diately after its discovery [1]. Since then, numerous bio- a topical problem, because the number of disease cases chemical and biomedical studies have been conducted in continues to rise. Moreover, individual features and pref- order to further improve insulin preparations. Detemir Glargin Glargin Chain A Aspart Lispro Chain B Fig. 1. Structure of insulin and its analogs (modified from [19]). BIOCHEMISTRY (Moscow) Vol. 83 Suppl. 1 2018 S148 SELIVANOVA et al. BIOSYNTHESIS AND SECRETION OF INSULIN erol. Inositol 1,4,5-trisphosphate is a ligand for the ER receptor proteins responsible for the release of intracellu- Insulin biosynthesis starts with the translation of lar calcium that results in an increased cytoplasmic Ca2+ mRNA for its precursor, preproinsulin. The precursor concentration. Finally, calcium ions stimulate insulin (110 a.a.) is encoded by the INS gene, a single copy of release from the secretory granules. Besides glucose, which is located in the short shoulder of chromosome 11 of other molecules that mediate insulin secretion have been the human genome [21]. Preproinsulin is synthesized only found: nicotinamide adenine dinucleotide phosphate on polyribosomes associated with the endoplasmic reticu- (NADP), glutamate and malonyl-CoA [25, 26], glycerol- lum (ER). The signal peptide (24 a.a.) of preproinsulin is 3-phosphate [27], and fatty acids [28, 29]. Insulin is cleaved off by the signal peptidase as the polypeptide is released from the cells through exocytosis: a mature translocated into the ER lumen [22] forming proinsulin. secretory granule fuses with the plasma membrane and In the ER, proinsulin folds into correct conformation with releases its content to the extracellular space. the formation of three disulfide bonds (B7–A7, B19–A20, A6–A11). Conversion of proinsulin into monomer insulin and C-peptide happens after proinsulin transport from the STRUCTURAL PROPERTIES AND SURFACE ER to the Golgi apparatus, where proinsulin is cleaved by CONTACTS IN THE INSULIN MOLECULE. peptidases in secretory vesicles, during which the C-pep- BINDING TO THE RECEPTOR tide (of 31 a.a.) located between fragments B and A is excised from the molecule. Insulin is then stored as a hexa- Immediately after insulin hexamers are secreted mer coordinated by two Zn2+ ions in β-cells of the from the β-cells and diffuse in the blood, a combination Langerhans islets in the pancreas [23, 24]. of electrostatic repulsion and insulin concentration gradi- An increase in the glucose blood level acts as a signal ent promotes dissociation of the hexamers into dimers for insulin secretion. As a rule, the process starts when the and monomers (only monomers exhibit biological activi- insulin-independent carrier protein Glut2 binds glucose ty). Therefore, hexamers are the storage form of insulin, molecules and transports them into β-cells of the while monomers are the biologically active form of this Langerhans islets. In β-cells, glucose is phosphorylated hormone (Fig. 2). by the enzyme glucokinase and eventually converted to Insulin monomer consists of chains A and B con- pyruvate via glycolysis. Pyruvate is oxidized in the tricar- nected by disulfide bonds.
Load more

Recommended publications
  • Enzymatic Assay of L-METHIONINE GAMMA-LYASE (EC 4.4.1.11)
    Enzymatic Assay of L-METHIONINE GAMMA-LYASE (EC 4.4.1.11) PRINCIPLE: L-Methionine Gamma-Lyase L-Methionine > Methanethiol + 2-Ketobutyrate + NH3 2-Ketobutyrate + MBTH > Azine Derivative Abbreviation used: MBTH = 3-Methyl-2-Benzothiazolinone CONDITIONS: T = 37°C, pH = 8.0, A320nm, Light path = 1 cm METHOD: Stopped Spectrophotometric Rate Determination REAGENTS: A. 100 mM Potassium Phosphate Buffer with 25 mM L-Methionine and 0.01 mM Pyridoxal 5-Phosphate, pH 8.0 at 37°C1 (Prepare 100 ml in deionized water using Potassium Phosphate, Monobasic, Anhydrous, Sigma Prod. No. P-5379, L-Methionine, Sigma Prod. No. M-9625, and Pyridoxal 5-Phosphate, Sigma Prod. No. P-9255. Adjust to pH 8.0 at 37°C with 5 M KOH.) B. 50% (w/v) Trichloroacetic Acid Solution (TCA) (Prepare 5 ml in deionized water using Trichloroacetic Acid, 6.1 N Solution, approximately 100% (w/v), Sigma Stock No. 490-10.) C. 1 M Sodium Acetate Buffer, pH 5.0 at 37°C (NaOAC) (Prepare 100 ml in deionized water using Sodium Acetate, Trihydrate, Sigma Prod. No. S-8625. Adjust to pH 5.0 at 37°C with 5 M HCl.) D. 0.1% (w/v) 3-Methyl-2-Benzothiazolinone Hydrazone (MBTH) (Prepare 10 ml in deionized water using 3-Methyl-2-Benzothiazolinone Hydrazone, Hydrochloride Hydrate, Sigma Prod. No. M-8006.) SSMETH01 Page 1 of 4 07/29/98 Enzymatic Assay of L-METHIONINE GAMMA-LYASE (EC 4.4.1.11) REAGENTS: E. 100 mM Potassium Phosphate Buffer with 1 mM Ethylenediaminetetraacetic Acid, 0.01% (v/v) 2-Mercaptoethanol and 0.02 mM Pyridoxal 5-Phosphate, pH 7.2 at 37°C (Enzyme Diluent)1 (Prepare 10 ml in deionized water using Potassium Phosphate, Monobasic, Anhydrous, Sigma Prod.
    [Show full text]
  • Lyxumia Subcutaneous Injection 300 Μg [Non-Proprietary Name] Lixisenatide (JAN*) [Name of Applicant] Sanofi K.K
    Report on the Deliberation Results May 31, 2013 Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau Ministry of Health, Labour and Welfare [Brand name] Lyxumia Subcutaneous Injection 300 μg [Non-proprietary name] Lixisenatide (JAN*) [Name of applicant] Sanofi K.K. [Date of application] June 11, 2012 [Results of deliberation] In the meeting held on May 24, 2013, the First Committee on New Drugs concluded that the product may be approved and that this result should be reported to the Pharmaceutical Affairs Department of the Pharmaceutical Affairs and Food Sanitation Council. The re-examination period for the product is 8 years, and the drug substance and the drug product are both classified as powerful drugs and the product is not classified as a biological product or a specified biological product. The proposed Japanese brand name should be changed for ensuring medical safety. *Japanese Accepted Name (modified INN) This English version of the Japanese review report is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail. The PMDA will not be responsible for any consequence resulting from the use of this English version. Review Report May 7, 2013 Pharmaceuticals and Medical Devices Agency The results of a regulatory review conducted by the Pharmaceuticals and Medical Devices Agency on the following pharmaceutical product submitted for registration are as follows. [Brand name] Lyxumia Subcutaneous
    [Show full text]
  • The Un-Design and Design of Insulin: Structural Evolution
    THE UN-DESIGN AND DESIGN OF INSULIN: STRUCTURAL EVOLUTION WITH APPLICATION TO THERAPEUTIC DESIGN By NISCHAY K. REGE Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy Department of Biochemistry Dissertation Advisor: Dr. Michael A. Weiss CASE WESTERN RESERVE UNIVERSITY August, 2018 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the thesis/dissertation of Nischay K. Rege candidate for the degree of Doctor of Philosophy*. Committee Chair Paul Carey Committee Member Michael Weiss Committee Member Faramarz Ismail-Beigi Committee Member George Dubyak Date of Defense: June 26th, 2018 *We also certify that written approval has been obtained for any proprietary material contained therein. Dedication This thesis is dedicated to my mother, Dipti, whose constant love and faith have never failed, to my father, Kiran, who taught me of the virtue of curiosity, and to my wife, Shipra, whose kindness and companionship have given me enough strength for eight lifetimes. i Table of Contents Dedication ..................................................................................................................................... i Table of Contents ......................................................................................................................... ii List of Tables ............................................................................................................................... v List of Figures ...........................................................................................................................
    [Show full text]
  • Genetic Studies of Leptin Concentrations Implicate Leptin in the Regulation of Early
    Page 1 of 93 Diabetes Genetic studies of leptin concentrations implicate leptin in the regulation of early adiposity Hanieh Yaghootkar1,2,3*&, Yiying Zhang4&, Cassandra N Spracklen5, Tugce Karaderi6,7,8,9, Lam Opal Huang10, Jonathan Bradfield11,12, Claudia Schurmann13, Rebecca S Fine14,15,16, Michael H Preuss13, Zoltan Kutalik1,17,18, Laura BL Wittemans6,19, Yingchang Lu13,20, Sophia Metz10, Sara M Willems19, Ruifang Li-Gao21, Niels Grarup10, Shuai Wang22, Sophie Molnos23,24, América A Sandoval-Zárate25, Mike A Nalls26,27, Leslie A Lange28, Jeffrey Haesser29, Xiuqing Guo30, Leo-Pekka Lyytikäinen31,32, Mary F Feitosa33, Colleen M Sitlani34, Cristina Venturini35, Anubha Mahajan6,36, Tim Kacprowski37,38, Carol A Wang22, Daniel I Chasman39,40, Najaf Amin41, Linda Broer42, Neil Robertson6,36, Kristin L Young43, Matthew Allison44, Paul L Auer45, Matthias Blüher46, Judith B Borja47,48, Jette Bork-Jensen10, Germán D Carrasquilla10, Paraskevi Christofidou35, Ayse Demirkan41, Claudia A Doege49, Melissa E Garcia50, Mariaelisa Graff43,51, Kaiying Guo4, Hakon Hakonarson11,52, Jaeyoung Hong22, Yii-Der Ida Chen30, Rebecca Jackson53, Hermina Jakupović10, Pekka Jousilahti54, Anne E Justice55, Mika Kähönen56,57, Jorge R Kizer58,59, Jennifer Kriebel23,24, Charles A LeDuc4, Jin Li60, Lars Lind61, Jian’an Luan19, David Mackey62, Massimo Mangino35,63, Satu Männistö54, Jayne F Martin Carli4, Carolina Medina-Gomez41,42, Dennis O Mook-Kanamori21,64, Andrew P Morris65,6,66, Renée de Mutsert21, Matthias Nauck67,38, Ivana Nedeljkovic41, Craig E Pennell22, Arund D Pradhan39,40, Bruce M Psaty68,69, Olli T Raitakari70,71,72, Robert A Scott19, Tea Skaaby73, Konstantin Strauch74,75, Kent D Taylor30, Alexander Teumer76,38, Andre G Uitterlinden41,42, Ying Wu5, Jie Yao30, Mark Walker77, Kari E North43, Peter Kovacs46, M.
    [Show full text]
  • OBSERVATIONS Sured, As Indicated in Fig
    LETTERS blood glucose concentrations were mea- lispro at 40 Ϯ 3 min and aspart at 49 Ϯ 3 OBSERVATIONS sured, as indicated in Fig. 1. If blood glu- min after injection, respectively (P ϭ cose was 3.5 mmol/l or lower, 20 ml 0.01). The maximum insulin concentra- glucose 30% was injected. One patient tion was 316 Ϯ 31 pmol/l on insulin lis- Direct Comparison of was excluded from the analysis because, pro and 295 Ϯ 27 pmol/l on insulin by mistake, he took a large extra dose of aspart (NS) (Fig. 1). The increase from 0 Insulin Lispro and insulin the night before the study. to 15 min after injection was 109 Ϯ 17 Aspart Shows Small Free insulin was measured after poly- pmol/l after injection of insulin lispro and Differences in ethylene glycol precipitation by Mercodia 53 Ϯ 11 pmol/l after injection of insulin Iso-Insulin (ELISA; Mercodia AB, Uppsala, Plasma Insulin aspart (P ϭ 0.02). Fasting insulin lispro Sweden), a two-site enzyme immunoassay levels reached 50% of peak concentration Profiles After containing two monoclonal antibodies at 20 Ϯ 1 min and aspart at 30 Ϯ 3 min against insulin. Identical results were ob- (P ϭ 0.02) (Fig. 2). The decrease of free Subcutaneous tained when equimolar concentrations of Injection in Type 1 insulin concentration from peak concen- human insulin, insulin lispro, and insulin tration to 50% of the maximum concen- aspart were tested, indicating 100% Diabetes tration was found at 113 Ϯ 10 min during cross-reactivity between lispro, aspart, insulin lispro and 154 Ϯ 14 min during and human insulin in this assay.
    [Show full text]
  • Thionein Can Serve As a Reducing Agent for the Methionine Sulfoxide Reductases
    Thionein can serve as a reducing agent for the methionine sulfoxide reductases Daphna Sagher*†, David Brunell*†, J. Fielding Hejtmancik‡, Marc Kantorow*, Nathan Brot§, and Herbert Weissbach*¶ *Center for Molecular Biology and Biotechnology, Florida Atlantic University, Boca Raton, FL 33431; ‡Ophthalmic Genetic and Visual Function Branch, National Eye Institute, National Institutes of Health, Bethesda, MD 20892; and §Department of Microbiology and Immunology, Hospital for Special Surgery, Cornell University Medical Center, New York, NY 10021 Contributed by Herbert Weissbach, April 7, 2006 It has been generally accepted, primarily from studies on methio- not been reported. Most in vitro studies have used DTT as the nine sulfoxide reductase (Msr) A, that the biological reducing agent reducing agent for both MsrA and MsrB, because this agent for the members of the Msr family is reduced thioredoxin (Trx), works very well with the Msr family of proteins. although high levels of DTT can be used as the reductant in vitro. Recently, the human MsrB genes have been of interest to us as Preliminary experiments using both human recombinant MsrB2 part of our studies on the role of the Msr system in protecting lens (hMsrB2) and MsrB3 (hMsrB3) showed that although DTT can and retinal cells against oxidative damage (18–20). Using a color- function in vitro as the reducing agent, Trx works very poorly, imetric assay for Msr activity, based on the reduction of the prompting a more careful comparison of the ability of DTT and Trx individual epimers of 4-N,N-dimethylaminoazobenzene-4-sulfonyl to function as reducing agents with the various members of the (DABS)-Met(o), we were surprised to find that Trx serves very Msr family.
    [Show full text]
  • Newborn Screening ACT Sheet [Increased Methionine] Homocystinuria (CBS Deficiency)
    American College of Medical Genetics ACT SHEET Newborn Screening ACT Sheet [Increased Methionine] Homocystinuria (CBS Deficiency) Differential Diagnosis: Classical homocystinuria (cystathionine ß-synthase (CBS) deficiency); hypermethioninemia due to methionine adenosyltransferase I/III (MAT I/III) deficiency; glycine n-methyltransferase (GNMT) deficiency; adenosylhomocysteine hydrolase deficiency; liver disease; hyperalimentation. Condition Description: Methionine from ingested protein is normally converted to homocysteine. In classical homocystinuria due to CBS deficiency, homocysteine cannot be converted to cystathionine. As a result, the concentration of homocysteine and its precursor, methionine, will become elevated. In MAT I/III deficiency and the other hypermethioninemias, methionine is increased in the absence of or only with a slightly increased level of homocysteine. YOU SHOULD TAKE THE FOLLOWING ACTIONS: . Contact family to inform them of the newborn screening result and ascertain clinical status. Consult with pediatric metabolic specialist. Evaluate the newborn with attention to liver disease and refer as appropriate. Initiate confirmatory/diagnostic tests in consultation with metabolic specialist. Educate family about homocystinuria and its management, as appropriate. Report findings to newborn screening program. Diagnostic Evaluation: Quantitative plasma amino acids will show increased homocystine and methionine in classical homocystinuria but only increased methionine in the other disorders. Plasma homocysteine analysis will show markedly increased homocysteine in classical homocystinuria and normal or only slightly increased homocysteine in the other disorders. Urine homocysteine is markedly increased in classical homocystinuria. Clinical Considerations: Homocystinuria is usually asymptomatic in the neonate. If untreated, these children eventually develop mental retardation, ectopia lentis, a marfanoid appearance including arachnodactyly, osteoporosis, other skeletal deformities and thromboembolism. MAT I/III deficiency may be benign.
    [Show full text]
  • Transfer of Β-Hydroxy-Β-Methylbutyrate from Sows to Their
    Wan et al. Journal of Animal Science and Biotechnology (2017) 8:2 DOI 10.1186/s40104-016-0132-6 RESEARCH Open Access Transfer of β-hydroxy-β-methylbutyrate from sows to their offspring and its impact on muscle fiber type transformation and performance in pigs Haifeng Wan†, Jiatao Zhu†, Caimei Wu†, Pan Zhou, Yong Shen, Yan Lin, Shengyu Xu, Lianqiang Che, Bin Feng, Jian Li, Zhengfeng Fang and De Wu* Abstract Background: Previous studies suggested that supplementation of lactating sows with β-hydroxy-β-methylbutyrate (HMB) could improve the performance of weaning pigs, but there were little information in the muscle fiber type transformation of the offspring and the subsequent performance in pigs from weaning through finishing in response to maternal HMB consumption. The purpose of this study was to determine the effect of supplementing lactating sows with HMB on skeletal muscle fiber type transformation and growth of the offspring during d 28 and 180 after birth. A total of 20 sows according to their body weight were divided into the control (CON, n = 10) or HMB groups (HMB, n = 10). Sows in the HMB group were supplemented with β-hydroxy-β-methylbutyrate calcium (HMB-Ca) 2 g /kg feed during d 1 to 27 of lactation. After weaning, 48 mixed sex piglets were blocked by sow treatment and fed standard diets for post-weaning, growing, finishing periods. Growth performance was recorded during d 28 to 180 after birth. Pigs were slaughtered on d 28 (n = 6/treatment) and 180 (n = 6/treatment) postnatal, and the longissimus dorsi (LD) was collected, respectively.
    [Show full text]
  • MEDICATION GUIDE ADLYXIN (Ad-LIX-In) (Lixisenatide) Injection
    MEDICATION GUIDE ADLYXIN (ad-LIX-in) (lixisenatide) injection, for subcutaneous use What is the most important information I should know about ADLYXIN? Do not share your ADLYXIN pen with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them. ADLYXIN can cause serious side effects including inflammation of the pancreas (pancreatitis), which may be severe and lead to death. Before using ADLYXIN, tell your healthcare provider if you have had: • pancreatitis • a history of alcoholism • stones in your gallbladder (cholelithiasis) These medical problems may make you more likely to get pancreatitis. Stop taking ADLYXIN and call your healthcare provider right away if you have pain in your stomach area (abdomen) that is severe, and will not go away. The pain may be felt going from your abdomen through to your back. The pain may happen with or without vomiting. These may be symptoms of pancreatitis. What is ADLYXIN? ADLYXIN is an injectable prescription medicine that may improve blood sugar (glucose) control in adults with type 2 diabetes, when used with diet and exercise. • ADLYXIN is not insulin. • ADLYXIN is not a substitute for insulin and is not for use in people with type 1 diabetes or people with diabetic ketoacidosis. • ADLYXIN has not been studied in people with a history of pancreatitis. • ADLYXIN has not been studied in people who use short-acting insulin. • ADLYXIN has not been studied in people who have a stomach problem that causes slow emptying of the stomach (gastroparesis). ADLYXIN is not for people with slow emptying of the stomach.
    [Show full text]
  • Networking Breakfast with ASBMR Leaders, NIH Representatives And
    8/20/2019 ASBMR Connect: Networking Breakfast with ASBMR Leaders, NIH Representatives and Senior Investigators September 20, 2019, 06:45 AM W308/Orange County Convention Center ASBMR Connect is supported in part by educational grants from Amgen, Inc. and Ultragenyx Pharmaceutical Inc. The Networking Breakfast with ASBMR Leaders, NIH Representatives and Senior Investigators is a ticketed event that is part of the ASBMR Connect Program. ASBMR Connect requires advance registration and a separate ticket fee. Registration Open September 20, 2019, 07:00 AM Valencia Ballroom Lobby/Orange County Convention Center Gerald D. Aurbach Lecture and Presentation of Esteemed Awards September 20, 2019, 08:00 AM Valencia Ballroom B-D/Orange County Convention Center Join your colleagues to celebrate the following ASBMR 2019 Esteemed Award Winners: William F. Neuman Award, Paula Stern Achievement Award, Stephen M. Krane Award and Adele L. Boskey Award From Genes to Genomes to Biology and Health • Richard Lifton MD, PhD, Rockefeller University September 20, 08:30 AM-09:30 AM Valencia Ballroom B-D/Orange County Convention Center Networking Break September 20, 2019, 09:30 AM Valencia Foyer/Orange County Convention Center Highlights of the ASBMR 2019 Annual Meeting September 20, 2019, 10:00 AM Valencia Ballroom B-D/Orange County Convention Center • Dana Gaddy PhD, College of Veterinary Medicine, Texas A&M University, United States, Chair • Shonni Silverberg MD, Columbia University College of Physicians & Surgeons, United States, Chair • Johannes Van Leeuwen PhD, Erasmus University Medical Center, Netherlands, Chair This special session is of interest to all health professionals, first time meeting attendees, young investigators, individuals new to the field, nurses, clinical research study coordinators, physical therapists and/or those seeking guidance in navigating through the extensive ASBMR program.
    [Show full text]
  • Advantages and Disadvantages of Different Treatment Methods in Achondroplasia: a Review
    International Journal of Molecular Sciences Review Advantages and Disadvantages of Different Treatment Methods in Achondroplasia: A Review Wiktoria Wrobel, Emilia Pach and Iwona Ben-Skowronek * Metabolic Laboratory, Department of Paediatric Endocrinology and Diabetology with Endocrine, Medical University in Lublin, Prof. A. Gebala Street 6, 20-093 Lublin, Poland; [email protected] (W.W.); [email protected] (E.P.) * Correspondence: [email protected]; Tel.: +48-817-185-440 Abstract: Achondroplasia (ACH) is a disease caused by a missense mutation in the FGFR3 (fibroblast growth factor receptor 3) gene, which is the most common cause of short stature in humans. The treatment of ACH is necessary and urgent because untreated achondroplasia has many complications, both orthopedic and neurological, which ultimately lead to disability. This review presents the current and potential pharmacological treatments for achondroplasia, highlighting the advantages and disadvantages of all the drugs that have been demonstrated in human and animal studies in different stages of clinical trials. The article includes the potential impacts of drugs on achondroplasia symptoms other than short stature, including their effects on spinal canal stenosis, the narrowing of the foramen magnum and the proportionality of body structure. Addressing these effects could significantly improve the quality of life of patients, possibly reducing the frequency and necessity of hospitalization and painful surgical procedures, which are currently the only therapeutic options used. The criteria for a good drug for achondroplasia are best met by recombinant human growth hormone at present and will potentially be met by vosoritide in the future, while the rest of the drugs Citation: Wrobel, W.; Pach, E.; are in the early stages of clinical trials.
    [Show full text]
  • Methionine Metabolism in Chronic Liver Diseases: an Update on Molecular Mechanism and Therapeutic Implication
    Signal Transduction and Targeted Therapy www.nature.com/sigtrans REVIEW ARTICLE OPEN Methionine metabolism in chronic liver diseases: an update on molecular mechanism and therapeutic implication Zhanghao Li1, Feixia Wang1, Baoyu Liang1, Ying Su1, Sumin Sun1, Siwei Xia1, Jiangjuan Shao2,3, Zili Zhang1,2,3, Min Hong1, Feng Zhang1,2,3 and Shizhong Zheng1,2,3 As one of the bicyclic metabolic pathways of one-carbon metabolism, methionine metabolism is the pivot linking the folate cycle to the transsulfuration pathway. In addition to being a precursor for glutathione synthesis, and the principal methyl donor for nucleic acid, phospholipid, histone, biogenic amine, and protein methylation, methionine metabolites can participate in polyamine synthesis. Methionine metabolism disorder can aggravate the damage in the pathological state of a disease. In the occurrence and development of chronic liver diseases (CLDs), changes in various components involved in methionine metabolism can affect the pathological state through various mechanisms. A methionine-deficient diet is commonly used for building CLD models. The conversion of key enzymes of methionine metabolism methionine adenosyltransferase (MAT) 1 A and MAT2A/MAT2B is closely related to fibrosis and hepatocellular carcinoma. In vivo and in vitro experiments have shown that by intervening related enzymes or downstream metabolites to interfere with methionine metabolism, the liver injuries could be reduced. Recently, methionine supplementation has gradually attracted the attention of many clinical researchers. Most researchers agree that adequate methionine supplementation can help reduce liver damage. Retrospective analysis of recently conducted relevant studies is of profound significance. This paper reviews the latest achievements related to methionine metabolism and CLD, from molecular 1234567890();,: mechanisms to clinical research, and provides some insights into the future direction of basic and clinical research.
    [Show full text]